What Are Growth Hormone Secretagogues
Growth hormone secretagogues (GHSs) are compounds that stimulate the pituitary gland to produce and release its own growth hormone. They are fundamentally different from exogenous HGH (recombinant human growth hormone), which injects synthetic GH directly into the body and progressively suppresses the pituitary’s natural production.
The distinction matters. GH secretagogues work with the body’s endocrine system. Exogenous HGH works instead of it. This difference impacts the GH release pattern (pulsatile vs flat), long-term pituitary function, cost, side effect profile, and how the body utilizes the growth hormone.
Why Growth Hormone Matters
Growth hormone is a 191-amino acid peptide hormone produced by somatotroph cells in the anterior pituitary gland. GH production peaks during puberty and declines approximately 14% per decade after age 30 — a process called somatopause. By age 60, most adults produce only 20-25% of their peak GH output.
GH decline is associated with:
- Loss of lean muscle mass (sarcopenia)
- Increased body fat, particularly visceral (abdominal) fat
- Reduced bone mineral density
- Thinner, less elastic skin
- Impaired wound healing and recovery
- Decreased deep sleep duration and quality
- Reduced exercise capacity and energy
- Cognitive decline and mood changes
GH secretagogues aim to restore GH output toward youthful levels without the cost, suppressive effects, and regulatory burden of pharmaceutical HGH.
The Natural GH Axis: How It Works
Understanding the GH axis explains why different secretagogues are combined and why timing matters.
The Players
- Hypothalamus — produces GHRH (growth hormone-releasing hormone) and somatostatin (growth hormone-inhibiting hormone)
- Anterior pituitary — somatotroph cells produce and store GH, releasing it in response to GHRH and ghrelin signals
- Liver — converts GH to IGF-1 (insulin-like growth factor 1), which mediates most of GH’s tissue-building effects
- Peripheral tissues — muscles, bones, skin, organs respond to both GH and IGF-1
The Signaling Cascade
- The hypothalamus releases GHRH in pulses, stimulating the pituitary to synthesize and prepare GH for release
- Simultaneously, ghrelin (from the stomach and hypothalamus) signals the pituitary to release the stored GH
- GHRH + ghrelin together produce a synergistic GH pulse — the “volume” (GHRH) and “trigger” (ghrelin) work together
- Somatostatin periodically inhibits GH release, creating the troughs between pulses that give GH its pulsatile pattern
- Released GH stimulates IGF-1 production in the liver
- IGF-1 and GH both feed back to the hypothalamus to reduce further GHRH release (negative feedback loop)
Why Pulsatile Release Matters
The body releases GH in 6-12 discrete pulses per day, with the largest pulse occurring during Stage 3/4 deep sleep. This pulsatile pattern is not incidental — the change in GH levels (the rise and fall) appears to be more important for biological effects than the absolute GH level.
Pulsatile GH release promotes:
- Lipolysis (fat burning) during the GH spikes
- Tissue repair during the large nocturnal pulse
- Preserved insulin sensitivity (sustained GH elevation causes insulin resistance; pulsatile does not to the same degree)
- Normal negative feedback regulation (the pituitary is not constantly stimulated)
This is why GHRH + GHRP combinations that produce sharp GH pulses are generally preferred over compounds like CJC-1295 with DAC or continuous MK-677 that create sustained, non-pulsatile elevation.
The Three Classes of GH Secretagogues
Class 1: GHRH Analogs (“The Volume Knob”)
GHRH analogs mimic growth hormone-releasing hormone — the hypothalamic signal that tells the pituitary to synthesize and prepare GH for release. They bind to the GHRH receptor on somatotroph cells.
| GHRH Analog | Half-Life | Route | Key Feature | Status |
|---|---|---|---|---|
| CJC-1295 (no DAC) / Mod GRF 1-29 | ~30 min | Injectable | Standard GHRH analog; pulsatile release | Research chemical |
| CJC-1295 (with DAC) | 6-8 days | Injectable | Long-acting; sustained elevation; less physiological | Research chemical |
| Sermorelin | ~10 min | Injectable | First GHRH analog to get FDA orphan drug designation; shorter acting | Research + compounding |
| Tesamorelin | ~26 min | Injectable | Only FDA-approved GHRH analog (Egrifta SV); approved for HIV lipodystrophy | FDA-approved (Rx) |
How they contribute to GH release: GHRH analogs increase the amplitude of GH pulses. They tell somatotroph cells to produce more GH and prepare it in secretory granules for release. They do not optimally trigger the release — that is the role of GHRPs.
Why they are rarely used alone: A GHRH analog without a GHRP produces a modest GH pulse. The combination produces 3-5x more GH than either alone because they activate complementary receptor pathways. Running a GHRH analog alone is like pressing the gas pedal in neutral — you are revving the engine but not engaging the gear.
Class 2: GHRPs (“The Trigger”)
Growth hormone releasing peptides activate the GHS-R1a receptor (ghrelin/growth hormone secretagogue receptor) on the pituitary. They trigger the release of stored GH — the gear that engages the engine.
| GHRP | GH Output | Selectivity | Cortisol | Prolactin | Appetite | Desensitization | Best For |
|---|---|---|---|---|---|---|---|
| Ipamorelin | Moderate | Highest | None | None | Minimal | Very slow | Most users, cutting, anti-aging |
| GHRP-2 | High | Moderate | Mild | Mild | Moderate | Moderate | Middle-ground GH boost |
| GHRP-6 | High | Low | Significant | Mild-moderate | Severe | Moderate | Bulking, appetite stimulation |
| Hexarelin | Highest | Lowest | Significant | Moderate-high | Moderate | Rapid (2-4 wks) | Short-term max GH only |
The selectivity spectrum: Ipamorelin activates almost exclusively GH release. Moving from Ipamorelin to GHRP-2 to GHRP-6 to Hexarelin, each subsequent peptide activates more non-GH pathways (cortisol, prolactin, appetite). More GH output, but more side effects.
Practical guidance: Ipamorelin is the standard for 80%+ of users. GHRP-2 is a reasonable alternative for users who want more GH output and can tolerate mild side effects. GHRP-6 is niche — primarily for bulking. Hexarelin has no practical role due to rapid desensitization.
Class 3: Ghrelin Mimetics (“The Oral Option”)
Ghrelin mimetics are non-peptide compounds that activate the same GHS-R1a receptor as GHRPs but are orally bioavailable.
| Ghrelin Mimetic | GH Output | Route | Dosing | Half-Life | Key Feature |
|---|---|---|---|---|---|
| MK-677 (Ibutamoren) | High (sustained) | Oral | Once daily | ~24 hours | No desensitization even after 2 years |
MK-677 is currently the only clinically studied oral GH secretagogue available. Its 24-hour half-life creates sustained, non-pulsatile GH elevation — pharmacologically different from the pulsatile release produced by GHRH + GHRP combinations. The tradeoffs are significant appetite stimulation (ghrelin pathway) and progressive insulin resistance with long-term use.
The Master Comparison Table
| Feature | CJC-1295 | Sermorelin | Tesamorelin | Ipamorelin | GHRP-2 | GHRP-6 | MK-677 |
|---|---|---|---|---|---|---|---|
| Class | GHRH | GHRH | GHRH | GHRP | GHRP | GHRP | Ghrelin mimetic |
| Route | Injectable | Injectable | Injectable | Injectable | Injectable | Injectable | Oral |
| Frequency | 2-3x daily | 1-3x daily | Daily | 2-3x daily | 2-3x daily | 2-3x daily | Once daily |
| Half-life | ~30 min | ~10 min | ~26 min | ~2 hrs | ~15 min | ~20 min | ~24 hrs |
| GH pattern | Pulsatile | Pulsatile | Pulsatile | Pulsatile | Pulsatile | Pulsatile | Sustained |
| GH output (alone) | Low-mod | Low | Moderate | Moderate | High | High | High |
| IGF-1 increase | 30-50% | 15-30% | 30-50% | 20-40% | 30-60% | 30-60% | 40-90% |
| Cortisol | None | None | None | None | Mild | Significant | None |
| Prolactin | None | None | None | None | Mild | Mild-mod | None |
| Appetite | None | None | None | Minimal | Moderate | Severe | Significant |
| Insulin impact | Minimal | Minimal | Minimal | Minimal | Mild | Mild | Worsens |
| Water retention | Mild | Mild | Mild | Mild | Moderate | Moderate | Mod-high |
| Desensitization | Minimal | Moderate | Minimal | Very slow | Moderate | Moderate | None |
| FDA status | Research | Research* | Approved (Rx) | Research | Research | Research | Research |
| Cost/month | $50-100 | $150-300 | $500-800 | $50-100 | $40-80 | $30-60 | $30-60 |
| Convenience | Low | Low | Low | Low | Low | Low | Very high |
*Sermorelin had prior FDA approval (Geref, 1997) but was voluntarily withdrawn from the market. It remains available through compounding pharmacies and has stronger legal standing than never-approved peptides.
How to Combine GH Secretagogues
The Synergy Principle
The single most important concept in GH peptide therapy is the GHRH + GHRP synergy. Combining one compound from each class produces dramatically more GH than either alone.
Published data demonstrates:
- GHRH analog alone: ~5-15 ng/mL GH peak
- GHRP alone: ~10-20 ng/mL GH peak
- GHRH + GHRP together: ~30-80 ng/mL GH peak
This is not additive — it is synergistic. The whole is greater than the sum of the parts because the two receptor pathways amplify each other.
Standard Combinations
| Combination | Use Case | Protocol |
|---|---|---|
| CJC-1295 + Ipamorelin | Gold standard; most users | 100 mcg CJC + 200-300 mcg Ipa, 2-3x daily |
| Sermorelin + Ipamorelin | Clinical / conservative | 200-300 mcg each, 1-2x daily (usually pre-sleep) |
| CJC-1295 + GHRP-2 | Stronger GH, moderate sides | 100 mcg CJC + 100-200 mcg GHRP-2, 2-3x daily |
| CJC-1295 + GHRP-6 | Maximum GH + appetite | 100 mcg CJC + 100-200 mcg GHRP-6, 2-3x daily |
| MK-677 solo | No-injection option | 10-25 mg once daily before bed |
| CJC+Ipa (training) + MK-677 (rest) | Hybrid coverage | Injectables on training days, oral on rest days |
What NOT to Combine
- Two GHRPs simultaneously — Ipamorelin + GHRP-2 together does not produce meaningfully more GH than either alone. They compete for the same receptor. Pick one.
- Two GHRH analogs simultaneously — CJC-1295 + Sermorelin is redundant. They target the same receptor.
- Three or more GH compounds daily — Total IGF-1 elevation becomes difficult to control, insulin resistance risk increases, and the marginal benefit of each additional compound diminishes. Advanced users who run CJC+Ipa + MK-677 should monitor bloodwork closely.
- Any GH secretagogue without monitoring — If you are running any GH protocol for more than 8 weeks, baseline and follow-up bloodwork is not optional.
Choosing Your Protocol
By Goal
| Goal | Recommended Protocol | Why |
|---|---|---|
| Anti-aging / longevity | CJC-1295 + Ipamorelin (pre-sleep) | Cleanest metabolic profile; pulsatile release during sleep |
| Body recomposition (cut) | CJC-1295 + Ipamorelin (2-3x daily) | No appetite disruption; no cortisol; pulsatile GH optimizes fat oxidation |
| Body recomposition (bulk) | CJC-1295 + GHRP-6, or MK-677 | Appetite stimulation supports caloric surplus |
| Sleep optimization | MK-677 10 mg before bed, or CJC+Ipa pre-sleep | Both significantly improve deep sleep; MK-677 has strongest sleep data |
| Injury recovery | CJC-1295 + Ipamorelin + BPC-157 | GH accelerates tissue repair; BPC-157 adds targeted healing |
| No-injection protocol | MK-677 (oral) | Only effective oral GH secretagogue; accept metabolic tradeoffs |
| Clinical / prescribed | CJC-1295 + Ipamorelin or Sermorelin + Ipamorelin | Standard anti-aging clinic protocols |
| Budget-conscious | MK-677 10 mg | $30-45/month, oral, once daily |
| Maximum GH elevation | CJC-1295 + GHRP-2 or GHRP-6 + MK-677 (alternating) | Advanced; requires monitoring |
By Experience Level
| Level | Protocol | Rationale |
|---|---|---|
| Beginner | MK-677 10 mg/day (oral) | No injections, simple dosing, low cost; learn how GH elevation feels |
| Beginner (injection-ready) | CJC-1295 + Ipamorelin 2x daily | Gold standard; learn reconstitution and injection technique |
| Intermediate | CJC-1295 + Ipamorelin 3x daily | Higher GH output; comfortable with protocol management |
| Intermediate | CJC+Ipa training days + MK-677 rest days | Hybrid coverage; balances pulsatile and sustained elevation |
| Advanced | CJC+Ipa + GHRP-2 or custom GHRP combination | Tailored to specific goals with bloodwork monitoring |
GH Testing and Monitoring
Essential Markers
| Marker | What It Tells You | When to Test | Target Range |
|---|---|---|---|
| IGF-1 | Primary measure of GH axis activity | Baseline, 8 weeks, then quarterly | 200-300 ng/mL (age-dependent; upper third of normal range) |
| Fasting glucose | Acute glucose regulation | Baseline, then monthly (MK-677 users) | <100 mg/dL |
| HbA1c | 3-month average glucose | Baseline, 12 weeks | <5.7% |
| Fasting insulin | Insulin resistance (precedes glucose elevation) | Baseline, 12 weeks | <10 mIU/L (optimal: <5) |
| HOMA-IR | Calculated insulin resistance index | Calculated from fasting glucose + insulin | <2.0 |
Additional Markers (GHRP-6 and Hexarelin Users)
| Marker | Why | When |
|---|---|---|
| AM cortisol | GHRP-6 and Hexarelin elevate cortisol | Baseline + 8 weeks |
| Prolactin | GHRP-6 and Hexarelin elevate prolactin | Baseline + 8 weeks |
How to Interpret IGF-1 Results
IGF-1 is the primary biomarker for assessing whether your GH protocol is working. It reflects cumulative GH exposure over weeks — a more reliable measure than a single GH blood draw (which only captures one moment in a pulsatile pattern).
| IGF-1 Result | Interpretation | Action |
|---|---|---|
| Below baseline | Protocol not working or peptide quality issue | Verify peptide quality (third-party CoA); reassess dosing |
| 10-30% above baseline | Modest response; typical for low-dose protocols | Continue or increase dose if desired |
| 30-60% above baseline | Good response; target range for most users | Maintain protocol |
| 60-100% above baseline | Strong response; typical for aggressive protocols | Monitor closely; consider dose reduction if above 300 ng/mL |
| >300 ng/mL (absolute) | Supraphysiological | Reduce dose; elevated IGF-1 carries theoretical long-term risks |
The Insulin Sensitivity Warning
All GH secretagogues can worsen insulin sensitivity to varying degrees because GH is a counter-regulatory hormone to insulin. GH promotes hepatic glucose output and impairs peripheral glucose uptake. The risk is dose-dependent and compound-dependent:
- Low risk: Ipamorelin, CJC-1295, Sermorelin, Tesamorelin (pulsatile release, minimal sustained GH elevation)
- Moderate risk: GHRP-2, GHRP-6 (direct ghrelin pathway activation affects glucose metabolism)
- Higher risk: MK-677 (sustained 24-hour GH elevation; documented fasting glucose elevation in trials)
Anyone with prediabetes (fasting glucose 100-125 mg/dL), metabolic syndrome, type 2 diabetes, or strong family history should use GH secretagogues cautiously and monitor glucose markers monthly.
GH Secretagogues vs Exogenous HGH
| Factor | GH Secretagogues | Exogenous HGH |
|---|---|---|
| Source of GH | Your own pituitary | Recombinant synthetic |
| GH pattern | Pulsatile (GHRH+GHRP) or sustained (MK-677) | Flat dose (non-pulsatile) |
| Pituitary suppression | None (stimulates, not replaces) | Progressive suppression with long-term use |
| IGF-1 increase | 20-90% (compound-dependent) | 50-200%+ (dose-dependent) |
| Cost | $30-200/month | $500-1,500/month |
| Convenience | Low (injectables) to high (MK-677) | Low (daily injection) |
| Prescription required | No (research chemicals) or yes (Tesamorelin) | Yes (controlled distribution) |
| Quality control | Variable (research) to GMP (compounding/Rx) | Pharmaceutical-grade |
| Side effect profile | Generally mild (compound-dependent) | Water retention, joint pain, carpal tunnel, insulin resistance |
| Legal status | Research chemicals or Rx | Prescription only; illegal for anti-aging/performance use |
| When HGH is superior | — | Clinical GH deficiency, bodybuilding-level supraphysiological dosing |
The bottom line: For most users seeking anti-aging, body composition, sleep, or recovery benefits, GH secretagogues provide 70-80% of the benefit of HGH at 10-20% of the cost, with a better safety profile and preserved pituitary function. HGH is only clearly superior when you need supraphysiological GH levels (bodybuilding) or have documented pituitary failure that prevents response to secretagogues.
Related Protocols
- CJC-1295 Protocol — full dosing, reconstitution, and cycle guide
- Ipamorelin Protocol — selectivity data, dosing, and clinical evidence
- MK-677 Protocol — oral dosing, insulin management, long-term use
- Sermorelin Protocol — legacy GHRH analog with FDA history
- Tesamorelin Protocol — the only FDA-approved GHRH analog
- Growth Hormone Stack — CJC-1295 + Ipamorelin combination protocol
- GH Peptides Compared — head-to-head comparison table
- CJC-1295 vs MK-677 — injectable vs oral GH peptide comparison
- GHRP-6 vs Ipamorelin — GHRP selectivity comparison
- Tesamorelin vs Sermorelin vs Ipamorelin — GHRH and GHRP comparison
- Reconstitution Calculator — exact dosing math for injectable GH peptides
Frequently Asked Questions
What is a growth hormone secretagogue? +
A growth hormone secretagogue is any compound that stimulates the pituitary gland to release growth hormone. Unlike exogenous HGH (which injects synthetic growth hormone directly), secretagogues trigger your body's own GH production. The three main classes are GHRH analogs (CJC-1295, Sermorelin, Tesamorelin), GHRPs (Ipamorelin, GHRP-2, GHRP-6, Hexarelin), and ghrelin mimetics (MK-677). They work through different receptor pathways and are often combined for synergistic effect.
Are GH secretagogues better than HGH injections? +
For most people, yes. GH secretagogues preserve your natural GH pulsatile release pattern, cost 5-10x less than pharmaceutical HGH ($100-200/month vs $500-1,500/month), and do not suppress your body's own GH production. HGH injections provide a flat, non-pulsatile dose that suppresses natural production over time. HGH is only superior for clinical growth hormone deficiency or bodybuilding-level supraphysiological dosing goals.
What is the best GH secretagogue for beginners? +
MK-677 is the easiest starting point — oral, once daily, no injections. For users comfortable with injections, CJC-1295 + Ipamorelin is the gold standard — it provides the cleanest, most physiological GH release pattern with minimal side effects. The choice depends on whether injection convenience or metabolic cleanliness is your priority.
Do GH secretagogues cause pituitary desensitization? +
It depends on the compound. MK-677 shows no pituitary desensitization even after 2 years of continuous use. Ipamorelin has minimal desensitization at standard doses. GHRP-2 and GHRP-6 show moderate desensitization over 8-12 weeks. Hexarelin desensitizes rapidly within 2-4 weeks. CJC-1295 and Sermorelin show minimal desensitization. Cycling (8-12 weeks on, 4 weeks off) mitigates desensitization for all compounds.
Can GH secretagogues be detected in drug tests? +
Yes. All GH secretagogues are prohibited by WADA (World Anti-Doping Agency) under category S2 — Peptide Hormones, Growth Factors, and Related Substances. Modern anti-doping testing can detect CJC-1295, Ipamorelin, GHRP-2, GHRP-6, Hexarelin, and their metabolites in urine and blood. MK-677 is detectable for extended periods due to its long half-life. If you are a tested athlete, all GH secretagogues are off-limits.